TVAX requests withdrawal of IPO citing market conditions
This article was originally published in Scrip
Executive Summary
TVAX Biomedical, a US startup focused on cell-based immunotherapies, is withdrawing its initial public offering filing, citing market conditions, according to a filing with the Securities and Exchange Commission.